Canntab Reaches Agreement with Innovative Bioinformatics Company, 36eight Technologies Inc.

Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has reached an agreement (the “Agreement“) with 36Eight Technologies Inc. (“36Eight“), a growing bioinformatics pharmacological healthcare data and technology company, which has developed  a proprietary artificial intelligence and machine learning algorithm which augments the  underlying clinical data/knowledge to efficiently understand a patient’s unique medical needs. 36Eight’s first-of-its-kind clinical intelligence software assists physicians, nurses, and pharmacists in screening for drug-cannabis interactions, and to optimize health outcomes via cannabis product dose combination, titration, and ongoing clinical assessment.

36Eight will list, market and support all of Canntab’s market-exclusive and patent-protected solid and exact dose products, which can be time released, extended released and ODT (oral dissolvable) in a variety of strengths and combinations, on its platform.

“This is an exciting opportunity for Canntab, as we believe 36Eight’s unique and valuable complementary platform will support our ability to provide effective solutions for patients while reinforcing the confidence of patients in their relationship with their clinical pharmacist,” said Larry Latowsky, CEO of Canntab. “When I was CEO of Katz Group Rexall, I had the pleasure of working on many initiatives with John Tse, 36Eight’s founder and CEO, when he was London Drugs’ Vice President overseeing their pharmacy division. As a licensed pharmacist himself, Mr. Tse fully comprehends the importance that optimizing outcomes with medical cannabis products requires careful care management, which is exemplified by 36Eight’s intelligent dosage platform.”

“Canntab’s product offerings are unlike any other product we support, as they are unique in that they provide exact dosage in a solid format, one that pharmacists and patients are comfortable with as a traditional delivery system,” said John Tse, 36Eight’s Founder and CEO. “We expect that with our software to support optimum care, our pharmacy partners will welcome and embrace Canntab’s products.”

Latowsky added, “This partnership is the first of many affiliate programs with health and wellness practitioners including pharmacists, doctors, chiropractors, naturopaths and sleep and pain clinics,” added Mr. Latowsky. “Our business model includes programs to reach millions of patients across Canada who will benefit from medical cannabis which will be accessible from our website, with the proper approval and direction from healthcare professionals. The number of Canadian Community Pharmacies alone is over 11,000. Programs like 36Eight and employing 36Eight’s platform in conjunction with our own educational platforms will support and optimize the effective prescription dosage of medical cannabis products.”

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the Company, Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes License, a Cannabis Research License, and an Industrial Hemp License from Health Canada.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

About 36Eight Technologies Inc.

36Eight is a clinical intelligence technology company focused on supporting clinicians to execute individualized medicine. Their bioinformatics platform is based on underlying clinical data/knowledge and the use of artificial intelligence and machine learning that determine optimization patterns from patient feedback and outcomes.

Primary Sponsor


Karma Koala Podcast

Top Marijuana Blog